文章：

动态对比增强计算机断层扫描预测的免疫评分可作为肝细胞癌免疫治疗敏感性的非侵入性生物标志物。

Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma

原文发布日期：11 March 2025

DOI: 10.3390/cancers17060948

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of the immunoscore linked to dynamic contrast-enhanced computed tomography (CECT).Methods: We performed immunohistochemical staining with CD3+and CD8+antibodies and counted the positive cells in the invasive margin (IM) and central tumor (CT), converting them to an immunoscore of 0 to 4 points. We assessed the dynamic CECT findings obtained from 96 patients who underwent hepatectomy for HCC and evaluated the relationship between dynamic CECT findings and immunoscores. For validation, we assessed the treatment effects on 81 nodules using the Response Evaluation Criteria in Solid Tumors in another cohort of 41 patients who received combined immunotherapy with atezolizumab and bevacizumab (n = 27) and durvalumab and tremelizumab (n = 14).Results: HCCs with peritumoral enhancement in the arterial phase (p< 0.001) and rim APHE (p= 0.009) were associated with the immunoscore in univariate linear regression analysis and peritumoral enhancement in the arterial phase (p= 0.004) in multivariate linear regression analysis. The time to nodular progression in HCCs with peritumoral enhancement in the arterial phase was significantly longer than that in HCCs without this feature (p< 0.001).Conclusions: We identified HCCs with peritumoral enhancement in the arterial phase as a noninvasive imaging biomarker to predict immune-inflamed HCC with a high immunoscore tendency. These HCCs were most likely to respond to combined immunotherapy.

摘要翻译： 

背景/目的：尽管免疫疗法是中期肝细胞癌（HCC）的主要治疗选择，但其疗效存在差异。本研究旨在通过动态增强计算机断层扫描（CECT）识别可预测免疫评分的非侵入性影像学生物标志物。 方法：我们采用CD3+和CD8+抗体进行免疫组织化学染色，计数肿瘤浸润边缘（IM）和中心肿瘤（CT）中的阳性细胞，并将其转换为0至4分的免疫评分。我们评估了96例接受肝切除术的HCC患者的动态CECT结果，并分析了动态CECT表现与免疫评分之间的关系。为验证结果，我们在另一队列的41例患者中（其中27例接受阿特珠单抗联合贝伐珠单抗治疗，14例接受度伐利尤单抗联合特瑞普利单抗治疗），采用实体瘤疗效评价标准评估了81个结节的治疗效果。 结果：单因素线性回归分析显示，动脉期瘤周强化（p<0.001）和边缘动脉期高强化（p=0.009）与免疫评分相关；多因素线性回归分析进一步证实动脉期瘤周强化（p=0.004）与免疫评分独立相关。具有动脉期瘤周强化的HCC结节进展时间显著长于无此特征的HCC（p<0.001）。 结论：我们确定动脉期瘤周强化可作为非侵入性影像学生物标志物，用于预测具有高免疫评分趋势的免疫炎症型HCC。此类HCC最可能对联合免疫治疗产生应答。

原文链接：

Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma